Some had hoped that its efficacy would more closely resemble that of existing injections on the market which can result in up to a 20% body weight loss while others noted the trial drop-out rate of 12% due to side effects or personal reasons
Liraglutide (Saxenda), an earlier GLP1 medication, uses a similar approach but has a shorter half-life of about 13 hours, requiring daily injection
At 30 M, luteolin completely suppressed the synthesis of IL-4 and CD40 ligand expression of anti-IgE and IL-3 stimulated purified basophils and PMA-stimulated KU812 basophils [170]
These landmark studies, required by regulatory authorities including the EMA and MHRA , have provided reassuring evidence about the cardiovascular safety profile of this drug class
Tolerability also depends on your dose trajectory and starting point
Updated July 23, 2026 Fact-checked by Dr